Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research

Dimerix Begins Phase 3 Recruitment for Kidney Disease Study in Mexico

September 12, 2024 03:15 AM CEST | By Team Kalkine Media
Dimerix Begins Phase 3 Recruitment for Kidney Disease Study in Mexico
Image source: shutterstock

Recent News

thumbnail

Ireland Emerges as Premier Tech Hiring Hub as EU Talent Landscape Shif...

thumbnail

Nordic APIs Launches API Security UnConference on October 13 Ahead of...

thumbnail

L-Soft Launches the Email Insights Learning Series on the 39th Anniver...

thumbnail

Precise Battery Management for RV Systems: A Technical Overview of lea...

Dimerix Limited (ASX:DXB) has announced the commencement of patient recruitment for its ‘ACTION3’ Phase 3 clinical trial. This significant milestone involves enrolling adolescent patients aged 12 to 17 with kidney disease in Mexico. The selection of this location marks a crucial step in advancing the clinical study. 

Expansion of Clinical Trial Sites 

In addition to the Mexican sites, Dimerix is expanding its research efforts to include 14 specialist pediatric clinical sites across Argentina, the United Kingdom, and the United States. This broadening of scope underscores the company's commitment to addressing pediatric kidney disease on a global scale. Furthermore, the appointment of Dr. Howard Trachtman, an esteemed nephrologist from NYU School of Medicine, to the Dimerix board highlights the company’s dedication to enhancing its expertise in nephrology. 

Dr. Trachtman expressed enthusiasm about continuing his collaboration with Dimerix, emphasizing the significant unmet need in treating Focal Segmental Glomerulosclerosis (FSGS). Despite its prevalence and serious outcomes in both children and adults, FSGS currently lacks approved therapies to delay or prevent progression to kidney failure. 

ACTION3 Trial Details and Funding 

The ACTION3 Phase 3 clinical trial will involve blinded, randomized participants who will receive either a placebo or DMX-200, with a follow-up period extending over two years. Dimerix has indicated that it possesses sufficient funds to support the study through its anticipated interim analysis, projected to occur around mid-2025. 

The trial aims to provide valuable insights into the efficacy and safety of DMX-200 for treating FSGS in adolescents. As Dimerix continues to progress with its clinical research, the company’s efforts are poised to contribute significantly to the field of nephrology and pediatric kidney disease treatment. 

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles